Q2 EPS Estimate for Vera Therapeutics Increased by Analyst

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush upped their Q2 2025 earnings estimates for Vera Therapeutics in a report released on Tuesday, May 6th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.71) for the quarter, up from their previous estimate of ($0.73). Wedbush has a "Neutral" rating and a $26.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($3.23) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($3.14) EPS, FY2028 earnings at ($2.13) EPS and FY2029 earnings at $0.81 EPS.

A number of other analysts have also issued reports on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target for the company. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. Finally, Cantor Fitzgerald decreased their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has an average rating of "Buy" and a consensus price target of $63.33.

Vera Therapeutics Stock Down 1.2%

Shares of VERA traded down $0.26 during mid-day trading on Friday, reaching $21.77. 1,262,456 shares of the stock traded hands, compared to its average volume of 778,875. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.34 and a beta of 1.28. The stock has a fifty day simple moving average of $24.22 and a 200 day simple moving average of $34.65. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the prior year, the firm posted ($0.56) EPS.

Hedge Funds Weigh In On Vera Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after purchasing an additional 10,916 shares during the period. Barclays PLC boosted its holdings in Vera Therapeutics by 94.1% in the third quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after purchasing an additional 41,394 shares during the period. Raymond James Financial Inc. acquired a new position in Vera Therapeutics in the fourth quarter worth $2,948,000. Victory Capital Management Inc. boosted its holdings in Vera Therapeutics by 515.0% in the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock worth $9,949,000 after purchasing an additional 197,014 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in Vera Therapeutics by 44.2% in the fourth quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company's stock worth $544,000 after purchasing an additional 3,942 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.